Baxter (BAX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street mostly rises as Fed holds key rate steady, deferring next likely hike to December
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- Oracle sets $225 billion revenue target for FY30 at investor day
- S&P Global explores potential separation of Capital IQ business
- Rivian shares slip ahead of Thursday earnings release
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Moderna stock rises on latest cancer vaccine data publication
Baxter Declares Quarterly Dividend
July 29, 2015 4:10 PM EDTDEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.
This dividend represents the new quarterly dividend rate for Baxter following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated, on July 1, 2015. Over its 84-year history, Baxter has consistently paid a dividend to shareholders and followed a disciplined approach to capital allocation that balances reinvestment in the businesses with returning significant value to shareholders.
''This quarterly dividend is... More
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
July 29, 2015 4:05 PM EDTCompany Achieves Significant Milestone with Successful Completion of Baxalta Incorporated Spin-Off, Poised for Profitable Growth
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today reported second quarter financial results that exceeded the companys previously issued guidance, and provided its complete financial outlook for the second half of 2015. The results for the second quarter of 2015 include the companys BioScience business, which was officially spun-off on July 1st and is now operating as a publicly traded biopharmaceutical company, Baxalta Incorporated (NYSE: BXLT).... More



